Business Wire

UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to Strengthen Aviation Security

18.2.2025 14:19:00 CET | Business Wire | Press release

Share

VentureOne and ADASI Partner to Integrate Advanced Autonomous Flight Technologies Powered by TII – Perceptra and Saluki Unveiled at IDEX 2025

As dual-use technologies increasingly drive economies of scale worldwide, ADASI, a leader in UAV system manufacturing, has announced their adoption of two advanced autonomous flight technologies by Abu Dhabi’s VentureOne: Perceptra, a new cutting-edge GPS-less navigation technology, and Saluki, a high-security flight control technology for autonomous systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218620933/en/

UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to Strengthen Aviation Security (Photo: AETOSWire)

These technologies, both developed by the Technology Innovation Institute, are designed to deliver secure, resilient operations in the most challenging environments. They have been optimized for UAV manufacturers, offering enhanced resilience, precision, and security for autonomous aerial operations. The agreement between VentureOne, ADASI, and TII was formalized at IDEX 2025, the Middle East’s largest defense exhibition, at which Saluki and Perceptra were unveiled.

Global Positioning System (GPS) technology has long been a fundamental pillar of navigation, supporting applications from everyday smartphone use to critical defense and military operations. However, this widespread reliance on GPS has exposed vulnerabilities that can be exploited through techniques like jamming and spoofing. Jamming occurs when signals on the same frequency overwhelm GPS receivers, preventing accurate location tracking, while spoofing involves transmitting counterfeit signals to deceive receivers into calculating incorrect positions or times. These vulnerabilities pose significant risks across sectors that depend on precise navigation, including autonomous drones, commercial aviation, and military aircraft.

In defense and security, compromised GPS signals can impact mission success and personnel safety, while in aviation, navigation errors may cause flight path deviations and operational disruptions – reports of which have the aviation industry and international regulators such as IATA and European regulator EASA seeking urgent solutions for GPS interference, according to one Reuters report in 2024.

For autonomous systems like drones and self-driving vehicles, the inability to maintain accurate positioning can create safety hazards, particularly in dynamic or high-risk environments, from aviation to defense. As the use of GPS-dependent systems continues to grow, the need for resilient, alternative navigation solutions has become increasingly critical. Perceptra and Saluki overcome many of today’s numerous challenges with advanced vision-based navigation, delivering reliable, resilient performance.

Dr. Najwa Aaraj, CEO of TII, said, “Perceptra, with its GPS-less capabilities, and Saluki, with its sophisticated Zero Trust architecture, represent a significant leap in autonomous navigation with the potential to transform multiple sectors. From supporting safe travel in commercial flights, search-and-rescue missions with precise navigation, to enabling efficient urban drone logistics for deliveries in densely populated cities, these technologies have broad real-world applications. Their adaptability also makes them invaluable in defense, ensuring secure and resilient operations in even the most challenging environments. This collaboration reflects our commitment to developing advanced, dual-use technologies that serve both civilian and defense needs while positioning the UAE as a leader in next-generation autonomous systems.”

Perceptra is a vision-based system that ensures reliable navigation without GPS, allowing aerial platforms to operate in GNSS-denied environments. It features visual relocking, low navigation errors, and easy integration across platforms for intelligence, surveillance, reconnaissance, and electronic warfare.

Saluki is a secure, high-performance flight controller and mission computer with Zero Trust architecture. With PX4 compatibility, Gen AI capabilities, and 300 TOPS compute power, it supports multi-vehicle management for mission-critical defense applications.

“At ADASI, we integrate only the most advanced, field-proven technologies to ensure our UAVs operate with unmatched precision, resilience, and security, even in the most contested environments,” said Juma Al Kaabi, the CEO of ADASI. “Perceptra and Saluki provide exactly what next-generation UAVs require: secure, GPS-independent navigation and AI-powered mission control.”

“VentureOne is dedicated to ensuring that cutting-edge research becomes reality to make a positive impact and transform industries,” said Reda Nidhakou, the Acting CEO of VentureOne. “Saluki and Perceptra are just two of many new innovations to come that will help ensure more resilient and safer drone operations in different sectors, starting with defense. We are working on a more comprehensive air autonomy and security portfolio that will play a central role in future drone operations.”

Last week, TII announced its collaboration with the General Civil Aviation Authority (GCAA) to support regulatory efforts by developing advanced methodologies for air corridor design. These methodologies aim to optimize flight routes and reduce the risk of aerial incidents in complex urban airspaces, ensuring safe and efficient navigation for both piloted and autonomous drone taxis. These efforts, alongside Perceptra and Saluki, reinforce Abu Dhabi’s vision to lead in next-generation navigation and AI-powered autonomy.

Both VentureOne and TII are part of the Advanced Technology Research Council (ATRC), which oversees Abu Dhabi’s research and development ecosystem to advance transformative technologies with global impact. ADASI is part of the EDGE Group, the advanced technology and defense conglomerate.

Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218620933/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye